Commentary|Videos|November 20, 2026

Can Intismeran Autogene Plus Pembrolizumab Improve Melanoma Outcomes?

Fact checked by: Melissa Venditti

ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.

Intismeran Autogene Adjuvant Data and Early-Line TIL Therapy in Melanoma

According to remarks from Karam Khaddour, MD, MS, a medical oncologist at Dana-Farber Cancer Institute, the phase 3 INTerpath-001 study (NCT05933577) showed that adding the individualized mRNA-based neoantigen therapy intismeran autogene (V940; mRNA-4157) to pembrolizumab (Keytruda) improved outcomes in patients with resected stage IIB to IV melanoma, and a small cohort study suggested tumor-infiltrating lymphocyte (TIL) therapy may have a role in earlier lines of treatment.1 Both sets of findings were reported at the 2026 European Society for Medical Oncology (ESMO) Congress.

Khaddour says the priority in melanoma care is to make innovative treatment available in a rational, personalized way rather than offering every treatment to every patient.

Study Design

INTerpath-001 is a randomized, double-blind, placebo- and active-comparator–controlled phase 3 trial sponsored by Merck Sharp & Dohme LLC in collaboration with ModernaTX, Inc. The study is evaluating adjuvant intismeran autogene plus pembrolizumab vs placebo plus pembrolizumab and has an estimated enrollment of 1089 patients. Eligible patients are 18 years or older with surgically resected cutaneous melanoma of stage IIB or IIC, III, or IV who are disease-free at consent and have received no prior systemic melanoma therapy.

The primary end point is recurrence-free survival (RFS), defined as time to recurrence, spread, or death from any cause, per investigator assessment. Secondary end points include distant metastasis–free survival, overall survival, safety, treatment discontinuation due to adverse events, and quality-of-life measures from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. The study is active, not recruiting.

Personalized Vaccine in the Adjuvant Setting

In INTerpath-001, the addition of investigational intismeran autogene to pembrolizumab improved RFS and distant metastasis–free survival compared with placebo plus pembrolizumab in patients with resected stage IIB to IV melanoma. Khaddour described the results as proof of concept that adding a personalized cancer vaccine can improve outcomes in the adjuvant setting.

TIL Therapy Moves Toward Earlier Lines

TIL therapy is currently approved for patients with melanoma that is refractory to anti–PD-1 therapy. Khaddour noted that cell therapies are generally more intensive regimens that require substantial multidisciplinary coordination and may be better suited to earlier lines of therapy.

Data presented at ESMO from a small cohort study evaluated TIL in addition to anti–PD-1 therapy in patients with melanoma who had not previously received anti–PD-1 therapy. The regimen produced an objective response rate of about 60%, a complete response rate of about 30%, and a median duration of response of 26 months.

Clinical Context and Limitations

Khaddour emphasized that the TIL findings come from a small study and are hypothesis-generating. The data suggest that, in the future, TIL-based treatment could be incorporated in earlier lines of therapy, when patients are more fit to receive it.

“This is exciting, but this is still a small study, and it's more of hypothesis-generating,” Khaddour says.

REFERENCE
1. A phase 3, randomized, double-blind, placebo- and active-comparator-controlled study of adjuvant intismeran autogene (V940, formerly mRNA-4157) plus pembrolizumab versus placebo plus pembrolizumab in high-risk stage II-IV melanoma (INTerpath-001). ClinicalTrials.gov. Updated September 24, 2025. Accessed November 19, 2026. https://clinicaltrials.gov/study/NCT05933577

Related to this article